BioHarvest SciencesBHST -1.37%63 Net Current Asset Value is $0.26 as of Mar. 2026, which is 98% below its 10-year median of 15.36. GuruFocus rates BHST with a GF Score™ of 63/100 and a GF Value™ of $8.58 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 1,050 Consumer Packaged Goods companies, BioHarvest Sciences ranks worse than 79.14% on this metric.
In calculating the Net Current Asset Value (NCAV), Benjamin Graham means a company's current assets (such as cash, marketable securities, and inventories) minus its total liabilities (including preferred stock, minority interest, and long-term debt).
BioHarvest Sciences's net current asset value per share for the quarter that ended in Mar. 2026 was $0.26.
The historical rank and industry rank for BioHarvest Sciences's Net Current Asset Value or its related term are showing as below:
BHST'
s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 11.04 Med: 15.36 Max: 16.69
Current: 11.04
During the past 12 years, the highest Price-to-Net-Current-Asset-Value Ratio of BioHarvest Sciences was 16.69. The lowest was 11.04. And the median was 15.36.
BHST's Price-to-Net-Current-Asset-Value is ranked worse than 79.14% of 1050
companies
in the Consumer Packaged Goods industry
Industry Median: 4.2
vs BHST: 11.04
BioHarvest Sciences (NAS:BHST) Net Current Asset Value Explanation
Benjamin Graham first discussed net current asset value (NCAV) in the 1934 edition of "Security Analysis", which he coauthored with David Dodd. In the book, (net) current asset value is defined as:" current assets alone, minus all liabilities and claims ahead of the issue."
The common definition of NCAV is: NCAV = current assets – [total liabilities + minority interest + preferred stock]
Net current assets exclude not only the intangible assets but also the fixed and miscellaneous assets. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.
One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Grahams strategy produced similar results.
Benjamin Graham looked for companies whose market values were less than two-thirds of their Net-Net Working Capital. They are collected under our Net-Net screener.
BioHarvest Sciences Net Current Asset Value Related Terms
BioHarvest Sciences Net Current Asset Value Historical Data
* Premium members only.
The historical data trend for BioHarvest Sciences's Net Current Asset Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BHST vs BRID, BOF, BFNH: Net Current Asset Value Comparison
For the Packaged Foods subindustry, BioHarvest Sciences's Price-to-Net-Current-Asset-Value, along with its competitors' market caps and Price-to-Net-Current-Asset-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BioHarvest Sciences Price-to-Net-Current-Asset-Value vs Consumer Packaged Goods Industry
For the Consumer Packaged Goods industry and Consumer Defensive sector, BioHarvest Sciences's Price-to-Net-Current-Asset-Value distribution charts can be found below:
* The bar in red indicates where BioHarvest Sciences's Price-to-Net-Current-Asset-Value falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Net Current Asset Value of $0.26 mean?
BioHarvest Sciences (BHST) has a Net Current Asset Value of $0.26 as of Mar. 2026. Ben Graham's net current asset value equals the per-share value of total current assets less total liabilities. View historical data on BioHarvest Sciences and its competitors. This is 98% below median its historical median of 15.36. Over the past decade, BioHarvest Sciences' Net Current Asset Value has ranged from 11.04 to 16.69. According to the industry distribution chart, BioHarvest Sciences ranks #831 out of 1050 companies in the Consumer Packaged Goods industry, placing it in the top 79.1%.
Is BioHarvest Sciences' Net Current Asset Value too high?
BioHarvest Sciences' current Net Current Asset Value of $0.26 is 98% below median its 10-year median of 15.36. Over the past 10 years, this metric has ranged from a low of 11.04 to a high of 16.69. The Consumer Packaged Goods industry median Net Current Asset Value is 4.20. BioHarvest Sciences' value of $0.26 is 93.8% below this industry median. Based on the distribution chart, BioHarvest Sciences ranks #831 out of 1050 companies in the Consumer Packaged Goods industry, which is in the bottom quartile relative to peers. Overall, BioHarvest Sciences has a GF Score™ of 63/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does BioHarvest Sciences' Net Current Asset Value compare to BRID and BOF?
According to the Consumer Packaged Goods industry distribution chart, BioHarvest Sciences ranks #831 out of 1050 companies for Net Current Asset Value. This places BioHarvest Sciences in the lower half of its industry. The industry median Net Current Asset Value is 4.20. BioHarvest Sciences' value of $0.26 is 93.8% below this benchmark. Historically, BioHarvest Sciences' own Net Current Asset Value has ranged from 11.04 to 16.69 over the past decade. While the company's 10-year median is 15.36 vs. the industry median of 4.20, BioHarvest Sciences has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Current Asset Value for a Consumer Packaged Goods company?
The median Net Current Asset Value among Consumer Packaged Goods companies is 4.20, based on 1,050 companies in the industry. Companies in the top quartile (top 25%) have a Net Current Asset Value significantly above this median, while those in the bottom quartile fall well below. However, Net Current Asset Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. BioHarvest Sciences's current Net Current Asset Value of $0.26 is 93.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Current Asset Value mean?
A high Net Current Asset Value can signal that a stock is expensive relative to its fundamentals. Ben Graham's net current asset value equals the per-share value of total current assets less total liabilities. View historical data on BioHarvest Sciences and its competitors. For the Consumer Packaged Goods industry, the median Net Current Asset Value is 4.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BioHarvest Sciences's current Net Current Asset Value is $0.26, which is 98% below median its own 10-year median of 15.36. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioHarvest Sciences stock overvalued right now?
Based on GuruFocus' analysis, BioHarvest Sciences (BHST) is currently considered Possible Value Trap. The stock's GF Value™ is $8.58, compared to a current price of $2.87 — trading 66.6% below its estimated fair value. The current Net Current Asset Value is $0.26, which is 98% below median its 10-year median of 15.36 and 93.8% below the Consumer Packaged Goods industry median of 4.20. BioHarvest Sciences' overall GF Score™ is 63/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Current Asset Value calculated?
Net Current Asset Value is calculated from a company's financial statements. For BioHarvest Sciences (BHST), the current Net Current Asset Value is $0.26 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BioHarvest Sciences (BHST) Overvalued in 2026?
Based on GuruFocus' analysis, BioHarvest Sciences stock appears to be undervalued.
The current stock price of $2.87 is trading 66.6% below its estimated GF Value™ of $8.58.
GuruFocus considers BioHarvest Sciences to be Possible Value Trap.
Key valuation signals for BHST:
Net Current Asset Value: $0.26 (98% below median its 10-year median of 15.36)
GF Value™: $8.58 vs. price of $2.87 (66.6% below fair value)
Industry Position: 93.8% below the Consumer Packaged Goods median (#831 of 1050)
No single metric tells the full story. See the BHST stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
BioHarvest Sciences Inc is the developer and owner of the patented bio-cell growth platform farming technology. The Company has two operating segments or business units: the Products business unit and the CDMO Services business unit. In identifying these operating segments, management generally follows the Company's service lines representing its main products and services. The Products Business Unit - Nutraceuticals: Research, development, manufacturing, marketing and sales of science-based health and wellness nutraceutical solutions which are manufactured and sold as dietary supplements, functional food and beverages. The CDMO Services Business Unit - comprising a Contract Development and Manufacturing Operation that offers pharmaceuticals, cosmeceuticals, nutraceuticals, and nutritions.
63GF Score
Get the complete analysis for BHST
Net Current Asset Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BHST has been successfully added to your 
